Global Psychiatry Partnering Deal Trends, Players and Financials Report 2020 – ResearchAndMarkets.com
October 7, 2020DUBLIN–(BUSINESS WIRE)–The “Global Psychiatry Partnering 2014-2020: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.
Global Psychiatry Partnering 2014 to 2020 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Psychiatry deals.
The report presents financial deal terms values for Psychiatry deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Psychiatry technologies and products.
Report scope
Global Psychiatry Partnering 2014 to 2020 includes:
- Trends in Psychiatry dealmaking in the biopharma industry since 2014
- Analysis of Psychiatry deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Psychiatry deal contract documents
- Comprehensive access to over 700 Psychiatry deal records
- The leading Psychiatry deals by value since 2014
- Most active Psychiatry dealmakers since 2014
Available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in Psychiatry dealmaking
2.1. Introduction
2.2. Psychiatry partnering over the years
2.3. Psychiatry partnering by deal type
2.4. Psychiatry partnering by industry sector
2.5. Psychiatry partnering by stage of development
2.6. Psychiatry partnering by technology type
2.7. Psychiatry partnering by therapeutic indication
Chapter 3 -Financial deal terms for Psychiatry partnering
3.1. Introduction
3.2. Disclosed financials terms for Psychiatry partnering
3.3. Psychiatry partnering headline values
3.4. Psychiatry deal upfront payments
3.5. Psychiatry deal milestone payments
3.6. Psychiatry royalty rates
Chapter 4 – Leading Psychiatry deals and dealmakers
4.1. Introduction
4.2. Most active in Psychiatry partnering
4.3. List of most active dealmakers in Psychiatry
4.4. Top Psychiatry deals by value
Chapter 5 – Psychiatry contract document directory
5.1. Introduction
5.2. Psychiatry partnering deals where contract document available
Chapter 6 – Psychiatry dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Psychiatry therapeutic target
Appendices
Appendix 1 – Directory of Psychiatry deals by company A-Z 2014 to 2020
Appendix 2 – Directory of Psychiatry deals by deal type 2014 to 2020
Appendix 3 – Directory of Psychiatry deals by stage of development 2014 to 2020
Appendix 4 – Directory of Psychiatry deals by technology type 2014 to 2020
For more information about this report visit https://www.researchandmarkets.com/r/lambca
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900